pravastatin has been researched along with sirolimus in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (70.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Berryman, ER; Gregory, CR; Griffey, SM; Katznelson, S; Kyles, AE | 1 |
| Berthier, S; Hartmann, S; Hubert, M; Kovarik, JM; Rordorf, C; Rosenkranz, B; Schneider, W | 1 |
| Crisby, M; Högberg, J; Pääjärvi, G; Roudier, E; Stenius, U | 1 |
| Iwao, H; Izumi, Y; Nakao, T; Shiota, M; Tatemoto, Y | 1 |
| Aliabadi, AZ; Dunkler, D; Grimm, M; Grömmer, M; Mahr, S; Wolner, E; Zimpfer, D; Zuckermann, AO | 1 |
| Bastiaansen-Jenniskens, YM; Bayon, Y; Boersema, GSA; Lange, JF; Utomo, L; van Osch, GJVM | 1 |
1 review(s) available for pravastatin and sirolimus
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for pravastatin and sirolimus
| Article | Year |
|---|---|
Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus.
Topics: Adult; Area Under Curve; Atorvastatin; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Interactions; Everolimus; Female; Half-Life; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Male; Mass Spectrometry; Middle Aged; Pravastatin; Pyrroles; Sirolimus | 2002 |
8 other study(ies) available for pravastatin and sirolimus
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Fluvastatin in combination with rad significantly reduces graft vascular disease in rat cardiac allografts.
Topics: Animals; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endocardium; Everolimus; Fatty Acids, Monounsaturated; Fluvastatin; Heart Transplantation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Immunosuppressive Agents; Indoles; Male; Monocytes; Myocardium; Pravastatin; Rats; Rats, Inbred F344; Rats, Inbred Lew; Sirolimus | 2001 |
HMG-CoA reductase inhibitors, statins, induce phosphorylation of Mdm2 and attenuate the p53 response to DNA damage.
Topics: Animals; Apoptosis; Cell Cycle Proteins; Cell Line, Tumor; Cells, Cultured; Cyclin-Dependent Kinase Inhibitor p21; DNA Damage; Enzyme Inhibitors; Female; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Situ Nick-End Labeling; Insulin; Liver; Liver Neoplasms; Nuclear Proteins; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Pravastatin; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-mdm2; Rats; Rats, Sprague-Dawley; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Serine; Sirolimus; TOR Serine-Threonine Kinases; Tumor Suppressor Protein p53 | 2005 |
Pravastatin induces rat aortic endothelial cell proliferation and migration via activation of PI3K/Akt/mTOR/p70 S6 kinase signaling.
Topics: Animals; Aorta; Blotting, Western; Cell Movement; Cell Proliferation; Cells, Cultured; Chromones; Dose-Response Relationship, Drug; Endothelial Cells; Enzyme Activation; Enzyme Inhibitors; Forkhead Box Protein O3; Forkhead Transcription Factors; Hepatocyte Nuclear Factor 3-alpha; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Mevalonic Acid; Morpholines; Phosphatidylinositol 3-Kinases; Phosphorylation; Pravastatin; Protein Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Ribosomal Protein S6 Kinases, 70-kDa; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases | 2007 |
Safety and efficacy of statin therapy in patients switched from cyclosporine a to sirolimus after cardiac transplantation.
Topics: Adrenal Cortex Hormones; Aged; Atorvastatin; Cholesterol; Cyclosporine; Dyslipidemias; Female; Heart Transplantation; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipoproteins, LDL; Male; Middle Aged; Postoperative Complications; Pravastatin; Pyrroles; Safety; Sirolimus; Treatment Outcome; Triglycerides | 2008 |
In vitro modulation of the behavior of adhering macrophages by medications is biomaterial-dependent.
Topics: Biocompatible Materials; Celecoxib; Cell Adhesion; Cells, Cultured; Chemokines, CC; Dexamethasone; Gene Expression; Humans; Inflammation Mediators; Interleukin-6; Macrophage Activation; Macrophages; Materials Testing; Monocytes; Phenotype; Polyesters; Polyethylene Terephthalates; Polypropylenes; Pravastatin; Sirolimus | 2017 |